Medical Robotic Systems Market Worth $17.89 Billion by 2022

Global Medical Robotic Systems Market revenue is expected to reach USD 17.89 billion by 2022, according to a new report by Grand View Research, Inc. Key drivers of this market include the increasing demand for robotic surgeries, constant improvement in healthcare infrastructure in emerging economies, improving reimbursement policies and increasing awareness levels amongst healthcare establishments, and practitioners.

According to data published by the U.S. FDA in 2012, approximately 450,000 robotic assisted surgeries were performed. The increase in prevalence of cancer, neurological disorders, spinal disorders, and prostate disorders are expected to further propel the demand for minimally invasive surgeries and consequently boost market growth. 

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/medical-robotic-systems-market

Further key findings from the study suggest:

• The introduction of new generation robotic systems integrated with advanced data recorders, remote navigation systems, HD microscopic cameras, data analytic systems, motion sensors; 3D-Imaging and robotic controlled catheters are further expected to boost demand over the forecast period
• Surgical robots was the largest product segment at over 60.0% in 2014, owing to the increasing number of robotic surgeries performed and increase in patient acceptance pertaining to assisted minimally invasive surgeries.
• Non medical hospital robotic systems are identified as the fastest growing product segment. Key factors accounting for this rapid growth include growing interest in telemedicine robots and cart robots which improve the automation in the hospital sector and also improve the patient care.
• On the basis of application, laparoscopy enabled systems accounted for the largest revenue share at 80.0% in 2014. Increase in geriatric population and rise in the prevalence of neurological disorders such as brain tumors, strokes, and spinal disorders are some factors expected to drive segment growth over the forecast period.
• In 2014, North America was the largest regional market with revenue share valued at over 40% owing to, the presence of advanced healthcare infrastructure, increasing demand for robot assisted surgeries, better reimbursement policies and the increasing geriatric population.
• Asia Pacific market is the most lucrative in terms of future growth. The presence of high unmet medical needs, growth in public and private healthcare investment, improving reimbursement framework, and the increasing healthcare expenditure levels.
• The global industry share is majorly dominated by companies such as Intuitive Surgical Inc., Mazor Robotics and Hansen. Other players like Accuray, S.R.L, Health robotics Varian, Reninshaw Plc. have developed products and applications catering to certain niche areas to establish market domination.

Grand View Research has segmented the Medical Robotic Systems market on the basis of product, application and region:
Product Outlook (Revenue in USD Million, 2012 - 2022)

• Surgical Robots
• Orthopedic Surgical Robots

• iBlock surgical system
• Robodoc surgical system
• Navio PFS surgical system
• MAKO RIO surgical system
• Stanmore Sculptor surgical system
• Neurosurgical Robotic Systems
• Pathfinder surgical system
• NeuroMate surgical system
• Renaissance surgical system
• Laparoscopy Robotic Systems
• FreeHand endoscope holder system
• Da Vinci robotic surgery system
• Telelap ALF-X surgical system
• Steerable Robotic Catheters
• Rehabilitation Robots
• Assistive Robots
• Prosthetics
• Orthotics
• Therapeutic Robots
• Exoskeleton Robotic Systems
• Noninvasive Radiosurgery Robots
• TrueBeam STx radiosurgery system
• CyberKnife robotic radiosurgery system
• Gamma Knife Perfexion radiosurgery system
• Hospital and Pharmacy Robots
• Telemedicine Robots
•  I.V. Robots          
• Pharmacy Robots
• Cart transportation robots
• Emergency response robotic systems
• LS-1 robotic system
• Auto Pulse Plus robotic system

Application Outlook (Revenue in USD Million, 2012 - 2022)

• Neurology
• Orthopedics robotic systems
• Laparoscopy
• Special Education

Regional Outlook (Revenue, USD Million, 2012 - 2022)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Asia Pacific
• Japan
• China
• Latin America
• Mexico
• Brazil
• MEA
• South Africa

Browse Related Category Reports @ https://www.grandviewresearch.com/industry/medical-devices

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Myelodysplastic Syndrome Drugs Market by Celgene, Amgen, Otsuka, and Takeda

The global Myelodysplastic Syndrome (MDS) Drugs Market size is expected to reach USD 2.4 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a 9.7% CAGR during the forecast period. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.

MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).

The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.

Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.

Access Research Report of Myelodysplastic Syndrome (MDS) Drugs Market @ https://www.grandviewresearch.com/industry-analysis/myelodysplastic-syndrome-mds-drugs-market

Further key findings from the report suggest:

• An estimated 60,000 people in U.S. are living with myelodysplastic syndrome, with approximately 10,000-15,000 new cases being reported annually
• U.S. dominated the global MDS drugs market with more than 48.0% share in 2016 owing to rising disease incidence and launch of strong pipeline candidates
• Emerging markets such as India, China, and South Korea are expected to exhibit lucrative growth during the forecast period due to favorable government policies, rising awareness about hematological malignancies, increased investment, and improved healthcare infrastructure
• Immunomodulatory drugs led the drug classes with a market share of more than 54.0% in 2016. Hypomethylating agents are projected to witness a double-digit decline in market share due to expected patent expirations
• Celgene, Amgen, Otsuka, and Takeda are some of the key players operating in this area; Celgene accounted for 95.2% of the market in 2016, driven by strong sales of Revlimid and Vidaza
• Currently, there are about 45 pipeline drugs in various stages of clinical development. Promising pipeline candidates such as Aranesp, luspatercept, Vyxeos, guadecitabine, and pevonedistat are expected to generate significant revenue upon launch.

Grand View Research has segmented the global myelodysplastic syndrome (MDS) drugs/Therapeutics market based on therapeutic class and major markets:

Myelodysplastic Syndrome (MDS) Drugs Market By Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)

• Hypomethylating Agents
• Immunomodulatory Drugs
• Anti-anemics

Myelodysplastic Syndrome (MDS) Drugs Market By Country Outlook (Revenue, USD Million, 2016 - 2022)

• U.S.
• U.K.
• Germany
• Spain
• France
• Italy
• Japan

Browse more reports of this category by Grand View Research @ https://www.grandviewresearch.com/industry/pharmaceuticals

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Research Insights on Cell Culture Market Size, Share, Trends and Analysis Report, 2022

The global Cell Culture Market is expected to reach USD 37.0 billion by 2022, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to the growing need for biopharmaceutical development, vaccine research and development, and protein production; all of which rely heavily on cytological R&D in which cell culture plays a pivotal role. 

The development and commercialization of integrated robotic liquid handling laboratory automation culture systems is also expected to considerably enhance growth over the forecast period. These systems provide highly improved capacity handling, higher efficiency and reproducible purity levels. 

Access Research Report of Cell Culture Market @http://www.grandviewresearch.com/industry-analysis/cell-culture-market

Further key findings from the report suggest:

• Cell culture sera accounted for over 50% of revenue generated in 2014 owing to, high usage rates of serum in the composition of cell cultures and their relatively high average market prices. Furthermore, commercialization of serum free sera is also expected to drive market demand in the coming years. 

• Culture reagents including amino acids, cofactors, thrombin, and growth factors, even though used in trace quantities, account for a considerably large share of revenue owing to their relatively expensive prices. 

• North America accounted for the largest share of this market in 2014, as there are a significantly high number of research and development projects ongoing in the region related to cytological investigation for proteomics, genomics, and drug and vaccine development. Growing need for biopharmaceuticals is also anticipated to fuel regional market growth during the forecast period. 

• Rising demand, for cell culture technology and cell biology research in Europe has shown significant development and companies have started investing in innovative technologies and advances in cell culture applications. 

• Asia Pacific is expected to witness significant growth in demand over the forecast period owing to the presence of high unmet need for increasing production and development of vaccines, drugs, and new biologics. Supportive government initiatives pertaining to increasing investments by manufacturers and governments in biopharmaceutical manufacturing and high untapped market opportunities are some important factors accounting for such rapid growth in demand. 

• Key participants of the cell culture market include Sartorius, Thermo Fisher Scientific, General Electric, Merck, Sigma-Aldrich Co., LLC, Corning, Lonza, Promocell, Becton, Dickinson & Company, and Eppendorf. 

• Market participants are involved in extensive R&D of 3D cell culture and full commercialization of the technologically advanced cell culture which offer higher accuracy of replication, greater purity and rapid growth 

Grand View Research has segmented cell culture market on the basis of consumables, products, applications and regions:

Cell Culture Consumables Outlook (Market Revenue in USD Billion, 2012 - 2022 )

• Media
• Minimum Essential Media (MEM)
• RPMI 1640 Media
• DMEM/F-12 Media
• F-10 Serum Free Media
• BME Media
• Insect Media
• Other Media
• Sera
• Fetal Bovine Serum
• Other Animals’ serum
• Reagents
• Albumin
• Other

Cell Culture Product Outlook (Market Revenue in USD Billion, 2012 - 2022 )

• Culture Systems
• Incubators
• Centrifuges
• Pipetting Instruments
• Biosafety Equipment
• Cryostorage Equipment

Cell Culture Applications Outlook (Market Revenue in USD Billion, 2012 - 2022 )

• Biopharmaceuticals
• Cancer Research
• Drug Development
• Gene Therapy
• Tissue Culture & Engineering
• Toxicity testing
• Vaccine Production

Cell Culture Regional Outlook (Revenue, USD Million, 2012 - 2022)

• North America
• Europe
• Asia Pacific
• RoW

Browse more reports of this category by Grand View Research @ https://www.grandviewresearch.com/industry/biotechnology

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Global Contraceptives Market is Estimated to Attain $30.86 million by 2022

Global Contraceptives Market is expected to reach USD 30.86 million by 2022, according to a new study by Grand View Research Inc. Growing prevalence of sexually transmitted infections (STIs), especially HIV and the introduction of new products exhibiting improved efficacy are expected to drive the contraceptives market over the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute towards the growth of the contraceptives industry.

In 2014, contraceptives device was the largest product segment with revenue estimated at over USD 12.0 billion. Devices such as condoms and contraceptive sponges, which are relatively inexpensive and easy to use, are expected to spearhead market growth over the forecast period. Female condoms are also expected to gain penetration rates over the next seven years. Growing user awareness levels and improving product availability are two key factors expected to drive segment growth.

Access Research Report of Contraceptives Market @ http://www.grandviewresearch.com/industry-analysis/contraceptives-market

Further key findings from the study suggest:

• Condoms are identified as the most lucrative sub segment of the contraceptive devices market. Low prices and abundant product availability are two key factors expected to drive the condoms market over the forecast period. The fact that, condoms are effective in preventing sexually transmitted diseases and unwanted pregnancies is also expected to boost usage rates.
• Intrauterine devices, especially hormonal IUDs are expected to experience attractive growth over the forecast period. Growing demand for Mirena, Jaydess and Skyla and the commercialization of Liletta is expected to further drive segment growth.
• The North American contraceptives market accounted for the largest revenue share in 2014. Presence of sophisticated healthcare infrastructure, high user awareness levels and abundant product availability are key factors attributing to the region’s market position.
• Latin America is expected to spearhead future market growth. Numerous government programs and free distribution of samples within the region are expected to help manufacturers capitalize on the available opportunities.
• Asia Pacific is also expected to witness substantial growth during the forecast period owing to, rapidly rising population levels and the consequent rise in demand for contraception. Presence of government initiatives in countries such as India, China, Sri Lanka, Pakistan, and Bangladesh aimed at slowing down population growth and prevalence of STDs are expected to promote market growth.

Browse more reports of this category by Grand View Research @ https://www.grandviewresearch.com/industry/pharmaceuticals

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Personalized Medicine Market is Estimated to Attain $2,452.5 Billion by 2022

Global Personalized Medicine Market is expected to reach USD 2,452.5 billion by 2022; according to a new study by Grand View Research, Inc. Growing number of approved companion diagnostics and biomarkers have aided the development of advanced personalized diagnostic tests and enhanced the level of treatment monitoring for a range of complex diseases. A significant number of diagnostics and therapeutic products, which are currently under clinical development and investigational research, are associated with one or the other proteomic or genomic markers and fall under category of companion diagnostics. Personalized medicine finds extensive and indispensable applications in the field of oncology. Furthermore, a marked technological advancement of next generation sequencing is expected to significantly enhance market usage rates owing to, a considerable decrease in the costs of whole genome sequencing and is expected to improve the demand for personalized medical diagnostic and therapeutic products over the forecast period. Personalized medical care and nutrition accounted for the largest share of the market in 2014 owing to, the presence of a significantly large consumer base, relatively less number of regulatory mandates, and the over-the-counter nature of retail nutrition products. This large share is also due to, the highly capital-intensive nature of implementation of healthcare information technology and telemedicine applications.

Access Research Report of  Personalized Medicine (PM) Market @
https://www.grandviewresearch.com/industry-analysis/personalized-medicine-market

Further key findings from the study suggest:

• Personalized nutrition and wellness was the largest product segment of the market in 2014. Growing population considerably high market usage and high accessibility are amongst key factors accounting for its large share. Moreover, the core segments of this market viz., personalized medicine diagnostics and therapeutics are expected to grow at the fastest rate over the forecast period due to, ongoing technological advancements in genetic medicine.
• North America was the largest regional market in 2014, with revenue estimated at over USD 500.0 billion. Presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to cancer research, and the presence of high patient and practitioner awareness levels are some key drivers of this market.
• Asia Pacific is expected to witness lucrative growth of over 13.0% over the forecast period. The presence of a large population base, high market penetration of segments such as complementary and alternative medicine, growing collaborative initiatives between western and eastern market participants are some key factors expected to drive regional market growth over the forecast period.
• Key players of this market include GE Healthcare, Illumina Inc., Quest Diagnostics, Abbott Diagnostics, Affymetrix, and Bayer Healthcare. Large presence of biotechnology and pharmaceutical manufacturers is expected to keep the industry rivalry at high levels throughout the forecast period. Moreover, the presence of extensive R&D to capitalize on novel growth opportunities is expected to further intensify competition over the forecast period.

Grand View Research has segmented the global personalized medicine market on the basis of product and region:

Global Personalized Medicine Product Outlook (Revenue, USD Billion, 2012 - 2022)

• PM Diagnostics
• Genetic Testing
• Direct-to-consumer Diagnostics
• Esoteric Lab Services
• Esoteric Lab Tests
• PM Therapeutics
• Pharmaceutical
• Genomic Medicine
• Medical Devices
• Personalized Medical Care
• Telemedicine
• Healthcare Information Technology
• Diseases Management
• Personalized Nutrition & Wellness
• Retail Nutrition
• Complementary Medicine
• Alternative Medicine

Personalized Medicine Regional Outlook (Revenue, USD Billion, 2012 - 2022)

• North America
• U.S.
• Canada

• Europe
• Germany
• UK
• Asia Pacific
• China
• Japan
• Latin America
• Brazil
• MEA
• South Africa

Browse more reports of this category by Grand View Research @ https://www.grandviewresearch.com/industry/pharmaceuticals

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Gaucher Disease Drugs Market is Anticipated to Exhibit 1.1% CAGR till 2025

San Francisco, 13 May 2019:

The global Gaucher Disease (GD) Drugs Market size is expected to reach USD 1.71 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.1% during the forecast period. Growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

Access Research Report with TOC @ https://www.grandviewresearch.com/industry-analysis/gaucher-disease-drugs-market

Further key findings from the report suggest:

• Type 2 is the rarest of the three forms of GD, with average mortality rate of less than two years
• Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme’s Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy, which is anticipated to register a CAGR of over 7.5% during the forecast period
• The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2025, on account of widening patient base and easy accessibility to treatments
• Some of prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson
• Sanofi Genzyme led the competitive space and is projected to continue holding prominent position in the market over the coming years, due to significant commercial performances of Cerezyme and Cerdelga

Grand View Research has segmented the global Gaucher disease drugs market based on type, therapy, and country:

Gaucher Disease Drugs Type Outlook (Revenue, USD Million, 2017 - 2025)

• Type 1
• Type 2
• Type 3

Gaucher Disease Drugs Therapy Outlook (Revenue, USD Million, 2017 - 2025)

• Enzyme Replacement Therapy
• Substrate Replacement Therapy

Gaucher Disease Drugs Country Outlook (Revenue, USD Million, 2017 - 2025)

• U.S.
• U.K.
• Germany
• Spain
• France
• Italy
• Japan

Access Press Release of Gaucher Disease Drugs Market @ https://www.grandviewresearch.com/press-release/global-gaucher-disease-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com